EuroBiotech: More Articles of Note


> GenSight Biologics named former Biogen VP Mohamed Genead, M.D. as its CMO. Genead worked as VP and global therapeutic area head for ophthalmology/retina gene therapy at Biogen, giving him a background that is a good fit for his new role. Novartis-backed GenSight is developing gene therapies to treat neurodegenerative retinal diseases. Statement

> Shares in Abivax jumped by more than 100% after it posted phase 2a data on its HIV candidate. Half of the 14 evaluable patients in the treatment arms experienced a reduction in viral load. No patients in the placebo arm experienced such a reduction. The data suggest ABX464 may be able to play a role in reducing the viral reservoirs present in patients with HIV. Release

> Lundbeck and Otsuka posted mixed, messy data from phase 3 trials of brexpiprazole in patients with Alzheimer’s disease. The two phase 3 trials set out to show the drug could lessen the agitation of Alzheimer’s patients but only one study hit its primary endpoint. And the partners spotted country-to-country variability in the data, with the drug performing worse in patients enrolled at trial sites in Russia. Lundbeck and Otsuka plan to discuss the data with FDA. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> GammaDelta appointed former GSK Oncology president Paolo Paoletti, M.D. as its CEO. Paoletti will lead a recently-established management team at the British immunotherapy startup. Ex-Pfizer researcher Natalie Mount, Ph.D. has joined as CSO. Dayle Hogg has also come on board as chief operating office. Release

> Z Factor raised £7 million ($9 million) to take a drug to treat alpha-1-antitrypsin deficiency into the clinic in 2019. Medicxi led the round, adding to the seed funding it previously put into Z Factor. The Series A continues a busy period in the relationship between Medicxi and the University of Cambridge’s Jim Huntington. In February, Medicxi led investments in two other Huntington startups, ApcinteX and SuperX. Statement

> TxCell teamed up with Inserm to develop CAR-Tregs for use in transplants and multiple sclerosis patients. The agreement positions the organizations to collaborate on the development of engineered CD8+ Treg cells to prevent transplant rejections and treat autoimmune diseases. TxCell’s internal research efforts have focused on engineered CD4+ Treg cells. Release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.